EPO levels of individuals experiencing AMS at any point of the study did not differ from AMS-free individuals at M1 (4.72 [3.02;5.66] mU/mL vs. 3.83 [2.54;5.67] mU/mL, p = 0.289) and M2 (12.07 [7.86;15.85] mU/mL vs. 9.52 [7.84;12.78] mU/mL, p = 0.410). This evidence concerns the gene EPO and ablepharon macrostomia syndrome.